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ABSTRACT
Lynch syndrome (LS) is an autosomal dominant disorder
caused by a defect in one of the DNA mismatch repair
genes: MLH1, MSH2, MSH6 and PMS2. In the last
15 years, an increasing number of patients have been
described with biallelic mismatch repair gene mutations
causing a syndrome referred to as ‘constitutional
mismatch repair-deficiency’ (CMMR-D). The spectrum of
cancers observed in this syndrome differs from that
found in LS, as about half develop brain tumours,
around half develop digestive tract cancers and a third
develop haematological malignancies. Brain tumours and
haematological malignancies are mainly diagnosed in
the first decade of life, and colorectal cancer (CRC) and
small bowel cancer in the second and third decades of
life. Surveillance for CRC in patients with LS is very
effective. Therefore, an important question is whether
surveillance for the most common CMMR-D-associated
cancers will also be effective. Recently, a new European
consortium was established with the aim of improving
care for patients with CMMR-D. At a workshop of this
group held in Paris in June 2013, one of the issues
addressed was the development of surveillance
guidelines. In 1968, criteria were proposed by WHO that
should be met prior to the implementation of screening
programmes. These criteria were used to assess
surveillance in CMMR-D. The evaluation showed that
surveillance for CRC is the only part of the programme
that largely complies with the WHO criteria. The values
of all other suggested screening protocols are unknown.
In particular, it is questionable whether surveillance for
haematological malignancies improves the already
favourable outcome for patients with these tumours.
Based on the available knowledge and the discussions
at the workshop, the European consortium proposed a
surveillance protocol. Prospective collection of all results
of the surveillance is needed to evaluate the
effectiveness of the programme.
INTRODUCTION
Lynch syndrome (LS) is an autosomal dominant
disorder caused by a heterozygous defect in one of
the DNA mismatch repair (MMR) genes, that is,
MLH1, MSH2 (and EPCAM deletion-mediated
MSH2 methylation), MSH6 or PMS2. Carriers of a
MMR defect have a high risk of developing colo-
rectal cancer (CRC), endometrial cancer and
various other cancers, most of which are diagnosed
between the ages of 40 years and 60 years.1 In the
last 15 years, an increasing number of patients have
been described with biallelic MMR gene mutations
in which MMR defects are inherited from both
parents. This leads to a syndrome with recessive
inheritance, which is referred to as ‘constitutional
mismatch repair-deficiency’ (CMMR-D). The spec-
trum of cancers observed in patients with this syn-
drome differs from the spectrum found in LS,2 as
about half develop brain tumours (BTs), around
half develop digestive tract cancers and a third
develop haematological malignancies. LS-associated
tumours such as endometrial and urinary tract
cancers also occur. A large proportion (up to 40%)
of patients with CMMR-D, even more than in LS,
develop metachronous second malignancies.2
The prognosis of CMMR-D is much worse than
that of LS due to the type of malignancies that
occur and the high risk of second primary tumours.
BTs and haematological malignancies are mainly
diagnosed in the first decade of life, and CRC and
small bowel cancer (SBC) in the second and third
decades of life. Endometrial cancers and urinary tract
cancers are diagnosed in young adult patients with
CMMR-D. A variety of non-malignant lesions may
also be observed in CMMR-D, such as cafe au lait
spots and other signs reminiscent of neurofibroma-
tosis type-I, hypopigmentation, mild immunoglobu-
lin deficiencies and congenital malformations.
Surveillance for CRC in patients with LS is very
effective, as regular colonoscopy has been shown to
reduce CRC-associated mortality by more than
60%.3 Therefore, an important question is whether
surveillance for the most common CMMR-D-
associated cancers might also be effective. In view of
the diverse nature of the malignancies associated with
the syndrome, it is not clear whether early detection
is possible and will improve the prognosis.
Recently, Durno et al4 published the outcome of
a surveillance programme of two sisters with
CMMR-D. Fifteen tumours were detected over a
follow-up period of 10 years, including a jejunal
carcinoma and a small asymptomatic anaplastic
astrocytoma that could be completely resected.
Sjursen et al5 reported on a patient who was fol-
lowed with upper and lower endoscopy, CT and
MRI at regular intervals over a period of 26 years.
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During this time six adenocarcinomas (of the left colon, the
duodenum, the distal ileum and the proximal ileum, the prox-
imal jejunum and the endometrium, respectively), as well as
several polyps of the large and small bowels and the stomach
were removed.
More than four decades ago, a WHO proposal defined the
criteria that should be met prior to implementation of large
scale population screening.6 These criteria can also be applied in
the assessment of surveillance of individuals with a genetic pre-
disposition to cancer. The most important criteria include: (A)
cancer should be a common problem in the group targeted for
surveillance; (B) the natural course of the cancers should be
known; (C) screening tests with high sensitivity and specificity
should be available and the tests should be acceptable to the
patient; (D) an effective treatment should be available following
detection of a tumour; (E) there should be evidence that screen-
ing leads to diagnosis of cancer at an early stage and to an
improvement in prognosis; and finally, (F) the surveillance
protocol should be cost-effective.
Recently, a new European consortium was established with
the aim of improving care for patients with CMMR-D. At a
workshop of this collaborative group held in the Saint-Antoine
Hospital, Paris, (9th of June, 2013), one of the issues addressed
was the development of surveillance guidelines. A total of
20 experts in the field, including human and clinical geneticists,
pathologists and paediatric oncologists from five countries, par-
ticipated in the meeting. Experts in the field not present at
the meeting were also involved in the discussions on surveil-
lance. In this manuscript, the most important WHO surveillance
criteria are addressed, and then applied to assess surveillance in
CMMR-D. Based on the outcome of the workshop and the
recommendations of European experts, the consortium now
proposes a surveillance programme. In view of the lack of
studies other than case reports, we did not use a system to grade
the category of evidence of reported studies and/or strength of
the recommendations.
WHAT IS THE TUMOUR SPECTRUM IN CMMR-D?
A total of 91 families with CMMR-D, including 146 patients,
were identified in the world literature (Wimmer et al, in prepar-
ation). The most frequent underlying gene defects were PMS2
mutations, which were reported in approximately 60% of cases.
The remaining 40% of cases were equally distributed among
MSH6 and MLH1/MSH2 biallelic mutation carriers. The various
cancers observed are summarised in table 1.
BTs and digestive tract cancers were the most common
cancers, identified in 53% and 40% of patients, respectively.
Among the BTs, the most common cancer was high grade
glioma, followed by primitive neuroectodermal tumours
(PNETs) and medulloblastoma. Glioblastomas and other high
grade gliomas were much more frequent in CMMD-R than
would be expected based on the relative contribution of these
BTs to total paediatric malignancies in the general population.
Digestive tract cancers included CRC (40% of all CMMR-D
cases) and SBC (12% of all cases). Haematological cancers were
observed in 31% and included mainly T cell non-Hodgkin
lymphoma (NHL) and acute leukaemia. Other LS-associated
cancers (endometrial cancer, urinary tract cancer) were also
observed in adults. In addition, a large variety of other tumours
were found (table 2). The distribution of ages at diagnoses for
BT, haematological malignancies, CRC and SBC reported in the
literature are shown in figures 1–4. It should be emphasised that
the age distribution is biased by collection of published cases.
CLINICAL DESCRIPTION AND NATURAL COURSE OF THE
MOST COMMON CANCERS OBSERVED IN CMMR-D
Brain tumours
Glioblastoma
Glioblastomas are tumours that originate from glia cells.
According to the WHO grading system (2007), these tumours
are classified as grade IV. The common symptoms and signs are
related to raised intracranial pressure and include headache,
nausea and/or vomiting and diplopia. Other symptoms include
epileptic insults, unusual behaviour, and signs and symptoms
caused by compression of parts of the brain and nerves.
The mean age at diagnosis in patients with CMMR-D is
9 years (range 2–40 years) (Wimmer et al, in preparation).
When a patient is diagnosed due to clinical symptoms, half of
all patients already have advanced disease. The diagnosis is sus-
pected with MRI or CT scanning and confirmed by histological
examination of a biopsy. Glioblastoma are characterised by
rapid progression, and the usual treatment consists of surgical
resection (if possible), followed by radiotherapy and/or chemo-
therapy depending on the age of the child. Due to diffuse
growth, complete resection of the tumour can be achieved in
less than 50% of cases7 and the reported 2-year survival in
patients with sporadic glioblastoma is 30–50%.7 8 The progno-
sis mainly depends on the completeness of the surgical resec-
tion. If the tumour is completely resected, a median survival of
Table 1 Overview of the most common cancers observed in 146
patients with CMMR-D (Wimmer et al, in preparation)
Type of tumours Number
Haematological malignancies











Small bowel cancers 18
Endometrial cancers 6
Other cancers 5
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukemia; CMMR-D,
constitutional mismatch repair-deficiency; CRC, colorectal cancer; NHL, non-Hodgkin
lymphoma; (S) PNET, (supratentorial) primitive neuroectodermal tumours.
Table 2 Other tumours observed in 146 patients with CMMR-D







Mucoepidermoid carcinoma of the parotis
Osteosarcoma
CMMR-D, constitutional mismatch repair-deficiency.
284 Vasen HFA, et al. J Med Genet 2014;51:283–293. doi:10.1136/jmedgenet-2013-102238
Cancer genetics
 group.bmj.com on April 16, 2014 - Published by jmg.bmj.comDownloaded from 
106 months has been reported.7 Glioblastoma is by far the most
common cause of death in CMMR-D, it is not known whether
the natural course and response to treatment of glioblastoma in
CMMR-D differ from that of sporadic cases.
Other brain tumours
Other BTs reported in CMMR-D include medulloblastoma and
(S)PNET. Medulloblastomas are located in the cerebellum and
(S)PNET in other parts of the brain. These tumours derive from
primitive neuroectodermal cells and are classified as WHO
grade IV tumours. The mean age at diagnosis in patients with
CMMR-D is 7 years (range 4–17 years). Frequently occurring
signs and symptoms are related to increased intracranial pressure
(nausea, headache, early morning vomiting) and are usually
already present for some time prior to diagnosis but go unrecog-
nised. In the general population, the estimated median delay
from the first symptoms to diagnosis is around 2 months.9
At presentation, about 30% of tumours have metastasised via
cerebrospinal fluid to other parts of the central nervous system.
The diagnosis can be established using MRI and CT scanning.
To evaluate whether the tumour has metastasised to the spinal
cord, spinal MRI and a lumbar puncture are necessary.
Treatment usually consists of surgical resection, radiotherapy
(except in cases <3 years old) and chemotherapy. The prognosis
is strongly dependent on the presence of metastases, and the
prognosis of patients without metastases is relatively good
(survival 75%) but neurocognitive consequences of brain radio-
therapy may impair patient quality of life. Again, it is unknown
whether the natural course of these tumours and the response
to treatment in CMMR-D differ from that of sporadic cases.
Digestive tract cancers: colorectal cancer and
small bowel cancer
CRC
It is generally accepted that most sporadic and hereditary colo-
rectal cancers originate from adenomas. This also appears to
hold for patients with CMMR-D, as colorectal adenomas are
found in a third of all patients.2
Several studies have described digestive tract cancers in
CMMR-D cases. In the 29 CMMR-D cases with CRC identified
by Durno et al,10 the mean age at diagnosis was 16.4 years
(range 8–28 years), 30 years younger than the typical age at
diagnosis of CRC in LS. Information on the presence of aden-
omas was provided for a total of 18 out of the 29 patients with
CRC. All but one had at least one adenoma, and 10 (55%) had
multiple adenomas with numbers usually between 10 and 100.
In addition, 11 out of 29 patients with CRC (38%) had multiple
CRCs. There was no predilection for a specific site in the
colorectum.
Herkert et al described four patients with CMMR-D with
intestinal cancer and polyposis and biallelic PMS2 mutations.
In addition, these authors identified all PMS2 CMMR-D cases
with gastrointestinal manifestations published in the literature
between 1980 and December 2009.11 They found 25 cases with
gastrointestinal (small bowel and colorectal) polyps (mean age at
diagnosis 17 years; range 7–46 years) and 42 cases with CRC
(mean age at diagnosis 19; range 8–48 years). Full information
on the colonic phenotype was available in 26 patients with CRC.
Multiple adenomas (>10 adenomas) were found in 18 out of the
26 (70%) patients with CRC and multiple CRC in 38% of the
cases.
Patients with CRC develop symptoms and signs, such as rectal
blood loss, at a relatively late stage, and around 50% of the
patients already have metastatic disease at diagnosis. The diagno-
sis of CRC is based on colonoscopy and confirmed by patho-
logical examination of a tumour biopsy. The preferred treatment
for CRC in young patients with LS is subtotal colectomy with
ileorectal anastomosis (or proctocolectomy and ileal-pouch anal
anastomosis in patients with rectal cancer). In patients with
CMMR-D with multiple polyps (if there are too many to remove
endoscopically and/or if they show high grade dysplasia) and
patients with CRC, the treatment of choice would be colectomy
with ileorectal anastomosis or proctocolectomy and construction
of an ileal pouch-anal anastomosis.
Patients with stage III CRC (and advanced stage II CRC)
receive chemotherapy, and those with rectal cancer are treated
Figure 1 Age at diagnosis of brain tumours.
Figure 2 Age at diagnosis of
lymphoma/leukaemia.
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with radiotherapy. No specific side effects of radiotherapy have
been reported in LS. However, the effectiveness and toxicity of
chemotherapy and radiotherapy in CMMR-D is largely
unknown (see below). Several studies have shown that there is
an accelerated adenoma-carcinoma sequence in LS. Patients may
develop CRC within 1–2 years after a normal colonoscopy. Our
experience, supported by data from the literature on CMMR-D,
indicates that adenoma and CRC development are also charac-
terised by rapid progression. The 5-year survival for CRC in LS
is approximately 50–60%.
Small bowel cancer
Cancer of the small bowel is also thought to originate from aden-
omas. Duodenal adenomas are found in 5% of CMMR-D cases
(Wimmer et al, in preparation). In a series of 42 primary SBCs in
LS, the mean age at diagnosis was 49 years (range 25–88 years),
about 10–15 years younger than in sporadic SBC.12 Based on 18
SBCs in 12 patients, the mean age at diagnosis in CMMR-D is
25 years (11–42 years) (Wimmer et al, in preparation).
Herkert et al11 identified 25 cases with gastrointestinal (small
bowel and colorectal) polyps (mean age at diagnosis 17 years;
range 7–46 years) in the medical literature, and 11 with SBC
(mean age at diagnosis 27; range 11–42 years).
About 50% of sporadic SBCs are located in the duodenum
and 10–15% in the ileum, whereas in LS the cancers are more
evenly distributed along the small bowel.12 The 11 PMS2
CMMR-D literature cases identified by Herkert et al11 devel-
oped 18 SBCs, including 8 duodenal cancers, 7 jejunal cancers
and 3 ileal cancers. Three of the 11 patients developed multiple
(up to 5) SBCs.5
In general, SBCs go unnoticed for a long period or manifest
with only non-specific symptoms such as dull, cramping abdom-
inal pain, abdominal distention and (faecal occult) blood loss.
Obstruction is also a common presentation.
The diagnostic modalities used for assessing the presence of
SBC are radiographic imaging (CT or MRI enteroclysis) and
endoscopy (upper gastrointestinal (GI) endoscopy and ileocolo-
noscopy, for the detection of cancers located in the duodenum
and ileum, respectively). There is also an increasing use of video
capsule endoscopy (VCE) and double balloon enteroscopy. The
effects of chemotherapy and radiotherapy are disappointing,13
and the treatment of choice is surgical resection. The 5-year sur-
vival rate of patients with resected tumours is around 50%. The




NHL is the most commonly occurring haematological cancer in
CMMR-D (Wimmer et al, in preparation), with T cell NHL
more frequently observed than B cell NHL. T cell NHL is
usually located in the mediastinum, while B cell NHL has a
mainly intra-abdominal location but is sometimes seen in the
cervical region. Signs and symptoms vary depending on the type
of lymphoma and the location, but may include coughing and
respiratory distress (T cell NHL), obstruction of the bowel
(B cell NHL), cervical lymphadenopathy, difficulty with swal-
lowing (also seen in B cell NHL), and anaemia, tiredness and
bruises in cases with bone marrow involvement.
Ages at diagnosis of sporadic NHL vary from 5 years to
12 years, according to histological subtypes.14 The median age
at diagnosis of NHL in CMMR-D is 5 years (range 0.4–
17 years), based on 31 cases (Wimmer et al, in preparation). In
the general population, the median time to diagnosis, defined as
the interval between the first signs and symptoms and diagnosis,
is relatively brief (3.8 weeks).9 The techniques used to diagnose
and stage NHL may include ultrasound of the abdomen, lymph
nodes and testes, MRI or CT scanning, fluorodeoxyglucose-posi-
tron emission tomography (FDG-PET) scanning, biopsy of the
tumour, bone marrow biopsy and lumbar puncture. Treatment
for NHL consists mainly of intensive chemotherapy, with radio-
therapy restricted to the small percentage of patients with overt
Figure 3 Age at diagnosis of colorectal cancer.
Figure 4 Age at diagnosis of small
bowel cancer.
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central nervous system (CNS) disease at the time of diagnosis.
The duration of treatment varies from a few weeks to 2 years,
depending on the stage and the histological subtype. The prog-
nosis is relatively good, with survival rates of 70–90%. The
natural course and response to treatment of NHL associated
with CMMR-D is unknown.
Acute leukaemia
The most common form of acute leukaemia in CMMR-D is
acute lymphoblastic leukaemia (ALL). The mean age at diagnosis
of ALL in CMMR-D is 6 years (range 2–21 years), based on
nine cases (Wimmer et al, in preparation). The incidence of ALL
peaks between 2 years and 5 years in non-CMMR-D. Children
with ALL often present with signs and symptoms that reflect
bone marrow infiltration and/or extramedullary disease includ-
ing anaemia, thrombocytopenia, neutropenia and lymphadenop-
athy. Other presenting signs and symptoms are bone pain, fever,
fatigue, bleeding and respiratory distress. The median time from
the presentation of signs and symptoms to diagnosis is only 1–2
weeks.9 Tests required to classify ALL include immunotyping,
cytogenetic studies and molecular studies to identify transloca-
tions. Lumbar puncture is performed to assess the involvement
of the CNS. The diagnosis of ALL is confirmed by a bone
marrow aspiration and biopsy. Although the treatment of ALL is
primarily based on chemotherapy, the different forms of ALL
require different approaches for optimal results. The prognosis
of ALL depends on the clinical and laboratory features and the
response to treatment. Overall, the cure rate of patients without
CMMR-D with ALL is greater than 80%.
CONSIDERATIONS REGARDING THE SURVEILLANCE
PROGRAMME IN PATIENTS WITH CMMR-D
Brain tumours
MRI scanning is the best screening method for the early detec-
tion of BT. Repeated CT scanning of the brain should be
avoided because of the possible induction of tumours due to
radiation.
As previously mentioned, glioblastomas usually show diffuse
growth, meaning that discrimination between normal and
tumour tissue may be impossible and the precise extent of the
tumour may be difficult to assess. MRI scanning in young chil-
dren is usually performed under general anaesthesia. MRI start-
ing from birth is recommended by Durno et al.4 The youngest
patients with CMMR-D diagnosed with glioblastoma were
2 years old. Therefore, we recommend commencing MRI
scanning at the age of 2 years, and due to rapid progression,
scanning at an interval of 6–12 months is probably needed.
Whether early detection will lead to more complete surgical
resections and improved survival is presently unknown.
Digestive tract cancer: CRC
Many studies have demonstrated that colonoscopy has the
highest sensitivity and specificity and is thus the best tool for
surveillance of the colon. In LS, small, flat and non-polypoid
lesions are frequent and can easily be missed.15 16 We also
observed mainly multiple non-polypoid lesions in a patient with
CMMR-D. Therefore, it is recommended that chromoscopy be
used in order to allow the detection and delineation of small,
flat lesions. In children, colonoscopy is performed under general
anaesthesia.
Based on experience with LS, surveillance of the colon is
expected to be effective. Due to the assumed high progression
rate from an adenoma to colorectal cancer, an intensive surveil-
lance programme at annual intervals is probably needed. In
patients with multiple adenomas, a shorter interval of 6 months
is recommended. Because most cancers develop in the second
decade of life, the programme can be started by the age of
8 years. In view of the large non-polypoid lesions often
observed in CMMR-D, a paediatric gastroenterologist should
perform the procedure together with an ‘adult’ gastroenterolo-
gist with experience of endoscopic mucosal resection of such
tumours.
Digestive tract cancer: small bowel cancer
For the detection of duodenal cancers, an upper GI endoscopy
can be performed (at the same time as colonoscopy). During
colonoscopy, the terminal ileum should also be intubated for
the identification of ileal cancer. CT scanning and MRI entero-
clysis can be used for the detection of SBC located in the
jejunum and remaining ileum but these modalities are too bur-
densome for surveillance purposes. A major disadvantage of
regular CT scanning is the radiation burden. VCE is probably
the best tool. Two studies in LS have shown that adenomas and
SBC can be detected using VCE. In a French study by Saurin,
tumours were detected in 10% of cases (one jejunal cancer, two
adenomas).17 However, in a Dutch study on 200 LS mutation
carriers, a tumour (one adenoma and one cancer) was identified
in only 1.5% of cases (Haanstra et al submitted 2013). In this
study, one patient developed a SBC 6 months after a normal
VCE. The value of surveillance of the small bowel using VCE is
therefore unknown. However, the high prevalence of such
tumours (8%) in CMMD-R may justify the use of VCE.
Because SBC below age 10 years is very rare, the surveillance
programme can be started at the age of 10 years. Young children
are generally able to swallow the capsule. An alternative is to
place the capsule endoscopically during upper GI endoscopy.11
Non-Hodgkin lymphoma
Because sporadic T cell and B cell lymphomas have an excellent
outcome, the benefit of early diagnosis is not obvious except for
the avoidance of life threatening situations at diagnosis for
patients with huge mediastinal masses. We currently have no
information on the natural history of these lymphomas in
CMMR-D, and while the natural course of the disease might
differ from sporadic cases, sporadic cases usually present with
rapidly growing tumours and clinical manifestations within a
month prior to diagnosis. Thus, screening at less than 3-month
intervals would probably be inefficient, whereas this frequency
is probably too high for a screening for which we are not sure
that it would improve the cure rate. A reasonable alternative is
to perform clinical examinations, and optionally, abdominal
ultrasound every 6 months. This strategy would probably be
inefficient for early diagnosis but it might provide useful infor-
mation on the natural history of this lymphoma in patients with
CMMR-D.
Acute lymphocytic leukaemia/acute myeloid leukaemia
Signs and symptoms of acute leukaemia are apparent within a
short period of time. As most patients with ALL have anaemia,
thrombocytopenia with a normal or depressed white blood cells
and lymphoblasts on peripheral smear, regular assessment of the
blood count may be recommended but it is uncertain whether
surveillance will lead to early detection and improvement of the
prognosis.
CHEMOTHERAPY IN LYNCH SYNDROME AND CMMR-D
About 15% of CRCs shows microsatellite instability (MSI),
which is a marker of MMR deficiency. In sporadic CRC, MSI
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results from somatic MMR inactivation mainly due to epigenetic
changes in the tumour, whereas in LS, MSI is caused by biallelic
MMR gene inactivation due to a heterozygous germ line muta-
tion and a somatic second-hit alteration in the other allele.
Patients with CMMR-D show MSI due to a constitutional MMR
defect caused by biallelic germ line MMR gene mutations.
A number of studies have evaluated the effectiveness of
chemotherapy in the subgroup of CRC with MMR deficient
versus MMR proficient tumours. Chemotherapy is the mainstay
of treatment of many cancers in childhood. Due to the rarity of
CMMR-D, very limited information on the optimal chemother-
apy is available. Several studies have demonstrated that tumours
with loss of MMR function are more frequently resistant to
certain forms of chemotherapy.18 Another major concern is that
some of these chemotherapeutic agents are mutagenic and may
increase the risk of developing therapy-induced cancers, because
patients with CMMR-D have a defect in DNA damage signal-
ling and are unable to repair the accumulated somatic
mutations.19
The effectiveness of chemotherapy in MMR-deficient CRC
has recently been reviewed by Devaud and Gallinger.20
Evaluation of clinical trials performed in the 20th century that
compared fluorouracil (5FU) with no treatment21 22 demon-
strated that MSI-high (MSI-H) tumours (retrospectively analysed)
were resistant to treatment with 5FU. These observations were
confirmed by many in vitro studies.23 The resistance to 5FU of
MMR-deficient cancer cells may be due to the incorporation of
fluorouracil metabolites into DNA, although the sensitivity of
MMR-deficient cell lines to this drug and other agents is likely to
be dependent on the status of HSP110, a molecular chaperone
that has been reported to be mutated in MMR-deficient tumours,
sensitising MSI-tumour cells to a wide spectrum of anticancer
agents including 5-FU24(Collura A, Gastroenterology, in press).
Although studies of MMR-deficient cell lines reported resist-
ance to cisplatin and carboplatin, a good response to oxaliplatin
was found and this was subsequently confirmed in clinical
trials.13 25–28 Irinotecan also appears to be effective, similarly as
in MMR-proficient tumours.29–32 Moreover, a recent study
using cell lines showed a good response to irinotecan in combin-
ation with thymidine.33
Most of the above mentioned studies were performed in
patients with somatic deficient MMR tumours. Less is known
about the response in patients with LS and patients with
CMMR-D with CRC.
All patients with CMMR-D with CRC and treated with
chemotherapy described in the literature are shown in
table 3.34–43 Most patients appear to show a response similar to
the response in patients with sporadic CRC. However, prospect-
ive studies are needed to confirm this observation.
In 2007, Scott et al44 discussed the effectiveness of chemo-
therapy in patients with CMMR-D. Several cell line and mouse
model studies showed that tumours are resistant to treatment
with O6-methylating agents.18 One of these agents (temozolo-
mide) is frequently used in the standard treatment of glioblast-
oma. This drug causes mutations in tumour DNA that cannot
be repaired by patients with a loss of MMR function. Indeed,














After 11 months alive
Gururangan/2007 CRC sigmoid PMS2 14 Pancolectomy 5FU, leucovorin Yes No evidence
recurrence
Died 7 years later from brain
tumour
Tan/2008 CRC PMS2 15 Low anterior resection FOLFOX4/12× No
Panproctocolectomy (3× CRC,
>10 polyps in specimen)




PMS2 14 Resection sigmoid, partial liver
resection; colectomy
Oxaliplatin, capacitabine. 5 months later recurrence rectal
cancer





Kruger/2008 Sigmoid CRC PMS2 13 Sigmoid resection, later
panproctocolectomy (multiple
polyps, CRC right colon)
FOLFOX/10 months No No evidence
recurrence
Alive
Rahner/2008 4× CRC MSH6 17 Colectomy Cetuximab No Not reported
Kratz/2009 CRC PMS2 8 Transversectomy FOLFOX Alive
Toledano/2009 Rectal cancer,
20 polyps
MSH2 14 Panproctocolectomy (100 polyps) FOLFOX Yes Relapse after 2 months
FOLFIRI/avastin Died 12 months after diagnosis
from brain tumour
Vasovcak/2012 Rectal cancer PMS2 13 Resection Capecitabine, oxaliplatin,
followed by cetuximab,
irinotecan
Resistant after 4 cycles










2 years later new liver
metastases; died from progressive
leukoencephalopathy
5FU, fluorouracil; CMMR-D, constitutional mismatch repair-deficiency; CRC, colorectal cancer; FOLFIRI, folinic acid, fluorouracil and irinotecan; FOLFOX, folinic acid, fluorouracil and
oxaliplatin; RFA, radio frequency ablation.
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investigation of a clinical specimen from a patient treated with
this drug showed an accumulation of somatic mutations
(mutator phenotype).45 In vitro studies showed a similar effect
for busulfan but not for chloroethylating agents such as cyclo-
phosphamide and melphalan.18
MSI occurs in some tumours following therapy with thiopurines
or cisplatin, suggesting that MMR deficiency is important in clin-
ical resistance.46–48 In addition, MMR deficiency appears to be
common in resistant acute myeloid leukemia and is a recurrent
feature of secondary NHL occurring in allografted patients treated
with azathioprine.49–51 A report on two patients with glioblastoma
showed that they were resistant to treatment with temozolo-
mide.52 Another study demonstrated loss ofMSH6 expression in a
subset of patients with glioblastoma resistant to temozolomide.53
All patients with CMMR-D known from literature with
BT35 36 38 43 44 52 54–58 and lymphoma38 52 57 59–63 that were
treated with chemotherapy are listed in tables 4 and 5. Most
patients with T cell lymphomas showed a good response to
chemotherapy. However, chemotherapy in patients with BT had
a less favourable outcome. In particular, only one out of six










Not specified Yes Partial remission Recurrence of BT Died at 12 years from
BT

























Alive at 13 years











Cisplatin CCNU vincristine Yes spinal
cord
Not reported MDS/AML at 9 Died 36 months later
Kruger/2008 Glioblastoma (PMS2) 6 Surgical
resection
Yes not specified Yes Complete
remission
Recurrent BT 10 years
later
Died at age 16 years
from relapse of BT
Kruger/2008 Glioblastoma (PMS2) 6 Surgical
resection
Yes not specified Yes Resistant Unresectable tumour Died at age 7 years
Ilencikova/2011 Fibrillar astrocytoma
(MSH6)





Yes Resistant Died 3 months later
Ilencikova/2011 Glioblastoma (MSH6) 10 Surgical
resection
Temozolomide Yes Resistant Progression Died at age 11 years
Johannes-ma/2011 Cystic glioma (PMS2) 11 Resection No No Recurrence after
7 months
11 Debulking Vincristine, carboplatin,
VP16, etoposide
Yes Partial response New tumour after





Yes Partial response Recurrence 3 years,
4 months later
18 temozolomide Yes Resistant Died at age 19 years
Baas/2013 Glioblastoma (PMS2) 3 Surgical
resection
Temozolomide Yes Partial response;
“26 months
healthy”
Died at 5 years










HIT-GBM-D protocol Yes Partial response Died at 6 years and














Died 2 years later from
liver metastasis
Yeung/2013 Optic pathway glioma
(PMS2)
3 No Carboplatin, vincristine, Partial response GH-excess Stable disease during
4½ years
8 Vinblastine followed by
temozolomide
Resistant Increased activity scan,
alive
5FU, fluorouracil; AML, acute myeloid leukemia; CCNU, Lomustine; CMMR-D, constitutional mismatch repair-deficiency; CRC, colorectal cancer; GH, growth hormone; NHL, non-Hodgkin
lymphoma, PNET, primitive neuroectodermal tumours.
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patients treated with temozolomide and radiotherapy showed a
partial response. In the other patients, the tumour was resistant
to treatment.
Whether temozolomide or other drugs such as cisplatin and
busulfan are contraindicated in CMMR-D is currently contro-
versial and requires further studies. As stated by Scott et al,44
early detection of tumours may allow considerations about the
most effective chemotherapeutic regimen.
DISCUSSION
For many types of cancers, diagnosis at the earliest possible
(preferably preclinical) stage results in much more effective
treatment and an improved prognosis. This may also be the case
for CMMR-D. Based on the available knowledge and the dis-
cussions at the workshop, the European consortium proposed a
surveillance protocol as summarised in table 6. The surveillance
for CRC is the only aspect that largely complies with the WHO
criteria for screening, although it is unknown whether colono-
scopic surveillance in CMMR-D is as effective as in LS. The
value of all other suggested screening protocols is unknown. In
particular, it is questionable whether surveillance for ALL and
NHL improves the already favourable outcome for patients with
these tumours. A randomised controlled trial is needed to assess
whether surveillance can improve the prognosis. However, the
question then arises whether it is ethically justified not to offer
surveillance in view of the high mortality without surveillance.







(years) Chemotherapy Other therapy Response Outcome/status
Ostergaard/
2005
T cell NHL MSH6 10 Yes No Partial remission Died from progression 6 months
later
Scott/2007 T cell NHL MSH2 2.5 BFM-NHL95 & MRC ALL 97/99 No Partial remission Recurrence 2 weeks after
completion of chemotherapy
2.5 MRC ALL R3 protocol (minus
cyclophosphamide) etoposide





Kratz/2008 T cell NHL PMS2 6 BFM-NHL95 No Complete
remission
Alive, 16 years
Kruger/2008 T cell NHL PMS2 10 Euro-LB 02 No Complete
remission
Alive




Relapse 9 months after diagnosis
8–9 ifosfamide, cisplatin, etoposide,
nelarabine
Radiotherapy Resistant Progression, died at age 9 years
Ripperger/
2010
T cell NHL MSH6 6 BFM-NHL95 No Not specified Relapse 6 months after
completion of chemotherapy




Alive 7 years later
Ilencikova/
2011
T cell NHL MSH6 11 Euro-LB 2002 Good response Died from BT <1 year
Baas/2013 T cell NHL MLH1 5.5 Children’s oncology group-A5971 No Died from staphylococcal sepsis
Baas/2013 B cell NHL PMS2 9 SNWLK-94 No Complete
remission
11years, 6 months: T cell NHL
Euro LB-02 protocol No Not reported
Baas/2013 T cell NHL PMS2 5.5 Euro LB-02 No “Initially good
response”
Died 9 months later from sepsis
during bone marrow aplasia
ALL, acute lymphoblastic leukaemia; CMMR-D, constitutional mismatch repair-deficiency; NHL, non-Hodgkin lymphoma.
Table 6 Surveillance protocol for patients with CMMR-D proposed by the European consortium
Type of cancer Lower age limit Procedure/interval
Brain tumours From age 2 years MRI, 1×/6–12 months
Digestive tract cancer
SBC From age 10 years VCE, upper gastrointestinal endoscopy*; 1×/year
CRC From age 8 years Ileocolonoscopy; 1×/year;
Haematological malignancies
NHL/other lymphoma From age 1 year Clinical examination 1×/6 months
Optional: abdominal ultrasound 1×/6 months
Leukaemia From age 1 year Blood count 1×/6smonths
LS-associated cancers† From age 20 years Gynaecological examination, transvaginal US, Pipelle curettage (1×/year),
Urine cytology, dipstick (1×/year)
All cancers Parents and patients should be advised to contact their doctor in case of unusual signs or symptoms. A pamphlet
should be available with information about the signs/symptoms that may occur.
*At the same time as colonoscopy under general anaesthesia.
†See: Revised guidelines for the clinical management of Lynch syndrome: HFA Vasen et al Gut 2013.
CMMR-D, constitutional mismatch repair-deficiency; CRC, colorectal cancer; LS, Lynch syndrome; SBC, small bowel cancer; NHL, non-Hodgkin lymphoma; VCE, video capsule endoscopy.
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As most parents/patients would probably choose to participate
in a surveillance programme, performing a trial would be diffi-
cult. The best approach may be to discuss the advantages and
disadvantages of surveillance and to make a joint decision
(table 7).
A general recommendation is that parents (or adult patients)
should contact their doctor if the child (adult patient) develops
unusual signs or symptoms. This is especially important in the
case of BT, in view of the rather long time to diagnosis.
The programme recommended by the consortium aims to
detect the most common cancers. However, a variety of other
tumours also occur in CMMR-D (table 2). A prospective rando-
mised trial may be performed to test whether a once yearly (rapid)
whole body MRI adds some efficacy to our screening programme.
As already mentioned above, it should be emphasised that the
distribution of ages at diagnosis of the various cancers is biased
by collection of published cases. In fact, ascertainment bias may
be a major issue in all that we know about this condition. As
further study is done, less severe cases may possible be seen
more frequently.
Nevertheless, the high risk of developing a wide variety of
cancers, the high risk of developing multiple cancers, some-
times synchronously, the occurrence of these cancers at a
young age and the need for intensive multimodal treatment in
the case of cancer, imposes an enormous burden on parents
and patients. A recent evaluation of psychological distress in
individuals predisposed to develop cancer showed increased
levels of distress in adults at risk of developing multiple
tumours.64 Nothing is known about the psychological distress
in patients with CMMR-D and their parents. Therefore,
doctors involved in the care of these patients should offer the
support of a psychologist.1 In addition, the clinical geneticist
plays an important role by organising presymptomatic testing
of other family members for CMMR-D or LS, and through
discussion of the option of prenatal or preimplementation
genetic diagnosis.
Individuals at risk for multiple cancers usually see several
doctors including paediatric oncologists, neurologists, (neuro)
surgeons, gastroenterologists and haematologists. It is important
that one of these specialists coordinates the surveillance exami-
nations and is available for the patients if they have questions.
A prerequisite for participation in a surveillance programme
is prospective collection of all results of surveillance, including
the response to treatment. With this aim in mind, the European
consortium established an EU-CMMR-D database. This
European registry will allow the (cost)effectiveness of the sur-
veillance programme to be evaluated and will allow the sensitiv-
ity of these tumours to chemotherapy to be assessed.
CONCLUSION
In an era of high-throughput sequencing technologies, an
increasing number of patients with CMMR-D are being identi-
fied. Most patients die from cancers in early childhood. The
only way to improve the prognosis is surveillance for these
cancers. Surveillance for CRC, and possibly SBC, might be
effective; however, the value of surveillance and early detection
of BT and NHL/leukaemia is unknown. The best approach is to
discuss the advantages and disadvantages of surveillance. When
patients and parents decide to participate, outcomes should be
collected and evaluated within the EU registry.
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Table 7 Pros and cons of participating in a surveillance programme
Pros Cons
1. Possible early detection of BTs, allowing complete resection
2. Early detection of adenomas in the small bowel and colorectum before malignant
degeneration
3. Early detection of BTs, which allows the most effective surgery and chemotherapeutic
regimen to be determined4. Early detection of NHL and leukaemia, which allows the
most effective chemotherapeutic regimen to be determined
1. Brain MRI may reveal small lesions of unknown significance. The only
management is follow-up MRI at a short interval, which may increase anxiety
2. Claustrophobia (MRI) in adults
3. Video capsule endoscopy: risk of retaining capsule
4. Colonoscopy: risk of perforation (1/1000) and risk of bleeding after
polypectomy (3–4%)
5. Greater awareness of being at high risk for developing cancers
6. Increased psychological distress before and after surveillance examination
7. Uncertainty about effectiveness of prevention programme and early
treatment8. Complications of general anaesthesia
BT, brain tumour; NHL, non-Hodgkin lymphoma.
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